Last reviewed · How we verify
Movantik
Movantik, marketed by AstraZeneca, is a therapeutic agent for opioid-induced constipation. Its key strength lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Movantik |
|---|---|
| Also known as | Naloxegol |
| Sponsor | AstraZeneca |
| Target | Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Therapeutic opioid induced constipation
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Flatulence
- Vomiting
- Headache
Serious adverse events
- Gastrointestinal perforation
- Opioid withdrawal
- Angioedema
- Rash
- Urticaria
- Severe abdominal pain
- Severe diarrhea
Key clinical trials
- The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients (PHASE3)
- Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer (PHASE2)
- Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation (PHASE4)
- Naloxegol Health Outcome Post Authorisation Safety Study
- Naloxegol Drug Utilization Post Authorisation Safety Study
- Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients (PHASE1)
- Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |